Format

Send to

Choose Destination
BJU Int. 2017 Feb;119(2):216-224. doi: 10.1111/bju.13578. Epub 2016 Aug 14.

Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.

Author information

1
Andros Men's Health Institutes, Arnhem, The Netherlands.
2
Center for Reproductive Medicine and Andrology, Martin Luther University Halle-Wittenberg, Halle, Germany.
3
Southwestern Medical Center, University of Texas, Dallas, TX, USA.
4
Sexual Medicine and Andrology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
5
University of Manchester, Manchester, UK.
6
Erasmus Medical Center, Rotterdam, The Netherlands.
7
Barnsley Hospital NHS Foundation Trust, Barnsley, UK.
8
Private Practice of Urology/Andrology, Hamburg, Germany.
9
Holly Cottage Clinic, Lichfield, Staffordshire, UK.
10
New England Research Institutes, Inc., Watertown, MA, USA.
11
Carlos Haya University Hospital, Málaga, Spain.
12
VU Medical Center, Amsterdam, The Netherlands.
13
Baylor College of Medicine, St. Luke's Episcopal Hospital, Houston, TX, USA.

Abstract

OBJECTIVES:

To evaluate the effects of testosterone-replacement therapy (TRT) on prostate health indicators in hypogonadal men, including rates of prostate cancer diagnoses, changes in prostate-specific antigen (PSA) levels and lower urinary tract symptoms (LUTS) over time.

PATIENTS AND METHODS:

The Registry of Hypogonadism in Men (RHYME) is a multi-national patient registry of treated and untreated, newly-diagnosed hypogonadal men (n = 999). Follow-up assessments were performed at 3-6, 12, 24, and 36 months. Baseline and follow-up data collection included medical history, physical examination, blood sampling, and patient questionnaires. Prostate biopsies underwent blinded independent adjudication for the presence and severity of prostate cancer; PSA and testosterone levels were measured via local and central laboratory assays; and LUTS severity was assessed via the International Prostate Symptom Score (IPSS). Incidence rates per 100 000 person-years were calculated. Longitudinal mixed models were used to assess effects of testosterone on PSA levels and IPSS.

RESULTS:

Of the 999 men with clinically diagnosed hypogonadism (HG), 750 (75%) initiated TRT, contributing 23 900 person-months of exposure. The mean testosterone levels increased from 8.3 to 15.4 nmol/L in treated men, compared to only a slight increase from 9.4 to 11.3 nmol/L in untreated men. In all, 55 biopsies were performed for suspected prostate cancer, and 12 non-cancer related biopsies were performed for other reasons. Overall, the proportion of positive biopsies was nearly identical in men on TRT (37.5%) compared to those not on TRT (37.0%) over the course of the study. There were no differences in PSA levels, total IPSS, or the IPSS obstructive sub-scale score by TRT status. Lower IPSS irritative sub-scale scores were reported in treated compared to untreated men.

CONCLUSIONS:

Results support prostate safety of TRT in newly diagnosed men with HG.

KEYWORDS:

#PCSM; #ProstateCancer; benign prostatic hyperplasia; disease registry; hypogonadism; testosterone

PMID:
27409523
DOI:
10.1111/bju.13578
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center